Rapid Therapeutic Announces Completion of New ISO 13485 Laboratory

DALLAS, Aug. 18, 2020 (GLOBE NEWSWIRE) — Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL) an SEC fully-reporting, growth-oriented aerosol manufacturing and marketing company focused on employing FDA-approved Metered Dose Inhaler (MDI) technology to deliver cannabinoid compounds, such as CBD, CBG, and CBN, announces its new ISO 13485 laboratory is ready to begin manufacturing the Company’s new consumer-focused, nhāler brand.
Chairman and CEO, Donal R. Schmidt, Jr. stated, “Our new laboratory allows RTSL to produce up to 2.9 million nhāler and Rxoid™ MDI per year. In addition, as demand increases, we can scale it to double the output with minimal additional personnel or capital outlay in about 9-12 weeks. It also reduces our manufacturing expenses and is a key process to eventual FDA approval of our MDI product line. Certainly, as we produce other aerosolized products in the future such as prescription medication, we will need this lab. I want to congratulate our team for getting the build-out finished on time and under budget.”Sean Berrier, SVP mentions, “RTSL now owns a state-of-the-art lab that complies with FDA guidelines for manufacturing class II medical devices. To my knowledge, no one in the CBD space has a lab of this quality. In the end, our product is about helping people and this lab assures RTSL manufactures safe MDI in a controlled environment so that consumers have absolute trust in our existing and future product lines.”About Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL)RTSL has developed and perfected a new method of formulating and manufacturing pressurized metered dose inhalers (pMDI) that contain and properly aerosolize proprietary formulae consisting of one or more cannabinoid compounds, such as CBD, CBG, and/or CBN.  The Company’s Rxoid™ and nhāler product lines are manufactured in compliance with Good Manufacturing Practices (GMP), on FDA-listed equipment. Note that while cannabinoids such as CBD, CBG and CBN are not yet approved by the FDA, under the laws of Texas and of many other states, it is legal to consume, sell and export them to legal jurisdictions.Properly formulated MDI deliver Active Pharmaceutical Ingredients (API) (drugs, nutraceuticals or bioceuticals) through the pulmonary tract. An MDI is the most efficient delivery method for an API other than an IV. In addition, MDIs are less expensive than any other route of delivery, based on the net cost per bioactive mg as tested in blood serum levels. However, MDIs are expensive to formulate and difficult to manufacture in order to deliver cannabinoid compounds to the level required by the FDA and FTC truth in labelling laws.  Ideally, a properly formulated, properly manufactured MDI containing cannabinoids will deliver exactly the same dose on its first use as well as its 100th use.RTSL’s MDIs are a safe and technically superior replacement for vape pens, mods and all-in-one products because they use no heat, function perfectly without using dangerous ingredients, and deliver a 98% bioavailable dose of CBD and/or cannabinoids directly to the systemic blood stream. This allows RTSL to manufacture a scientifically sound and superior alternative to all other cannabinoid vaping systems in a market estimated to be $5 billion in annual sales.RTSL will market nhāler through digital marketing campaigns and Rxoid™ products will continue to be sold directly to pharmacies and physicians who treat GAD, PTSD and other stress and anxiety disorders.  nhāler can be purchased online at www.nhaler.com.  Rxoid™ can be purchased by consumers online, at www.rxoid.com. RTSL also produces white label products for select commercial clients.We encourage all individuals to do their own research regarding cannabinoids, the use of MDI and our products. RTSL makes no claims about therapeutic benefits of its products. None of our products are intended to diagnose, treat, cure, or prevent any disease. Always consult a physician prior to using any cannabinoid product. If you experience any adverse reaction stop use immediately and seek appropriate medical attention. RTSL’s products are not approved by the FDA or under the Food Drug & Cosmetics Act (FD&C Act).Visit our corporate website at www.rtslco.com.Forward-Looking Statements This press release may contain forward-looking statements. In particular, when used in the preceding discussion, the words “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar expressions are intended to identify forward-looking statements. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of RTSL, its divisions and concepts to be materially different than those expressed or implied in such statements. These risk factors and others are included from time to time in filings made by RTSL with the Securities and Exchange Commission, including, but not limited to, in the “Risk Factors” sections in its Form 10-Ks and Form 10-Qs and in its Form 8-Ks, which we have filed, and file from time to time, with the U.S. Securities and Exchange Commission. These reports are available at www.sec.gov. Other unknown or unpredictable factors also could have material adverse effects on RTSL’s future results and/or could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements. The forward-looking statements included in this press release are made only as of the date hereof. RTSL cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.Contact:
Donal (Don) R. Schmidt, Jr.
Chairman and CEO
info@rtslco.com
Phone: 800-497-6059
Fax: 877-676-8527Source: Rapid Therapeutic Science Laboratories, Inc.Copyright © 2020 RTSL, Inc. All Rights Reserved.